Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL5156009 | 0.96 | GRIN2D (0.39) | VCAM1TDP1ATMGRIN2DGRIN3B | |
| SCHEMBL25252333 | 0.82 | GPR35 (0.41) | VCAM1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18894107 | 0.82 | VCAM1 (0.47) | VCAM1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31321220 | 0.82 | VCAM1 (0.47) | VCAM1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL104470 | 0.80 | TDP1 (0.52) | VCAM1TDP1ATMGRIN2DGRIN3B | |
| SCHEMBL9705273 | 0.78 | VCAM1 (0.41) | VCAM1TDP1ATMGRIN2DGRIN3B | |
| SCHEMBL309612 | 0.75 | VCAM1 (0.55) | VCAM1TDP1ATMGRIN2DGRIN3B | |
| SCHEMBL2875344 | 0.74 | VCAM1 (0.42) | VCAM1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23137518 | 0.74 | VCAM1 (0.46) | VCAM1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2653023 | 0.74 | VCAM1 (0.47) | VCAM1MAPTALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | MICROBIOTIX, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3548034-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | Microbiotix, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018106667-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8129403-B2 | e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| WO-2011090095-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | 富山化学工業株式会社 (JP) | 2011-07-28 | — | — | WO | disclosed |
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2009-09-10 | — | — | US | disclosed |
| US-20080176872-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| EP-1853588-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1853588-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| CN-1968933-A | Pyrazole derivatives useful for the treatment of cancer | ASTRAZENECA AB (SE) | 2007-05-23 | — | — | CN | disclosed |
| EP-1742921-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006087530-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2005103010-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176872-A1 | Chemical Compounds | TP53, XPOT, KRAS | VCAM1 3313/4885TDP1 3122/4885ATM 1464/4885 |
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | PRMT7, PRMT1, ZC3HAV1 | VCAM1 3340/4885TDP1 4512/4885ATM 4115/4885 |
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | NPC1L1, NPC1, GBA1 | VCAM1 871/4885TDP1 3695/4885ATM 4809/4885 |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | NPC1L1, NPC1, GBA1 | VCAM1 871/4885TDP1 3695/4885ATM 4809/4885 |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | TP53, XPOT, KRAS | VCAM1 3313/4885TDP1 3086/4885ATM 1540/4885 |
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | TP53, PDK2, PDK1 | VCAM1 4408/4885TDP1 1315/4885ATM 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.